Filtros de búsqueda

Lista de obras de

A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia

artículo científico publicado en 2004

A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia

artículo científico publicado en 2009

A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia

artículo científico publicado en 2010

A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.

artículo científico publicado en 2016

A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia

artículo científico publicado en 2014

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

artículo científico publicado en 2008

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens

artículo científico publicado en 2006

A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia

artículo científico publicado en 2015

A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia

artículo científico publicado en 2011

Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells

artículo científico publicado en 2015

Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia

artículo científico publicado en 2011

Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells

artículo científico publicado en 2017

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

artículo científico publicado en 2008

Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report

artículo científico publicado en 2017

Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes

artículo científico publicado en 2005

Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia

artículo científico publicado en 2003

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

artículo científico publicado en 2003

Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

artículo científico publicado en 2010

Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy

scientific article published on 01 October 2018

Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy

artículo científico publicado en 2004

Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene

artículo científico publicado en 2008

Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center

artículo científico publicado en 2007

At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells

artículo científico publicado en 2016

Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells

artículo científico publicado en 2006

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

artículo científico publicado en 2014

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib

artículo científico publicado en 2016

BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia

artículo científico publicado en 2016

CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia

artículo científico publicado en 2014

Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia

artículo científico publicado en 2017

Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia

artículo científico publicado en 2005

Central nervous system Richter's transformation and parvovirus B19 infection

artículo científico publicado en 2013

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment

artículo científico publicado en 2009

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia

artículo científico publicado en 2010

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

artículo científico publicado en 2005

Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients

artículo científico publicado en 2008

Chronic lymphocytic leukemia in African Americans ⬇️

artículo científico publicado el 9 de julio de 2012

Chronic lymphocytic leukemia: treatment options for patients with refractory disease

artículo científico publicado en 2009

Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship

artículo científico publicado en 2016

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).

artículo científico publicado en 2009

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction

artículo científico publicado en 2015

Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis

artículo científico publicado en 2014

Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center

artículo científico publicado en 2013

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide

artículo científico publicado en 2018

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

artículo científico publicado en 2006

Clofarabine combinations as acute myeloid leukemia salvage therapy

artículo científico publicado en 2008

Clofarabine plus low‐dose cytarabine followed by clofarabine plus low‐dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients ⬇️

artículo científico publicado el 26 de enero de 2012

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2013

Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment

artículo científico publicado en 2017

Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

artículo científico publicado en 2016

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

artículo científico publicado en 2003

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens

artículo científico publicado en 2015

Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia

artículo científico publicado en 2017

Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex

artículo científico publicado en 2017

Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia

artículo científico publicado en 2014

Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3 ⬇️

artículo científico publicado el 5 de julio de 2011

Current guidelines in defining therapeutic strategies

artículo científico publicado en 2004

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia ⬇️

artículo científico publicado el 13 de junio de 2011

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience

artículo científico publicado en 2009

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

artículo científico publicado en 2013

Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation.

artículo científico publicado en 2016

Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy

artículo científico publicado en 2018

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin

artículo científico publicado en 2008

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia

artículo científico publicado en 2003

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome

artículo científico publicado en 2003

Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia

artículo científico publicado en 2008

Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival

artículo científico publicado en 2015

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.

artículo científico publicado en 2014

Eradication of minimal residual disease in hairy cell leukemia

artículo científico publicado en 2006

Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

artículo científico publicado en 2015

Evidence-based mini-review: the role of alkylating agents in the initial treatment of chronic lymphocytic leukemia patients with the 11q deletion

artículo científico publicado en 2010

Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia

artículo científico publicado en 2011

FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia

artículo científico publicado en 2014

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia

artículo científico publicado en 2011

Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2015

Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen

artículo científico publicado en 2016

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia

artículo científico publicado en 2010

Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia

artículo científico publicado en 2004

Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia ⬇️

artículo científico publicado el 29 de julio de 2013

Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia

artículo científico publicado en 2015

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

artículo científico publicado en 2011

Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years

artículo científico publicado en 2009

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit

artículo científico publicado en 2003

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia ⬇️

artículo científico publicado el 12 de julio de 2011

Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia

artículo científico publicado en 2016

Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes

artículo científico publicado en 2012

High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome

artículo científico publicado en 2015

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

artículo científico publicado en 2003

Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma

artículo científico publicado en 2017

Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia

artículo científico publicado en 2017

Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia

artículo científico publicado en 2018

Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology

artículo científico publicado en 2007

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data

artículo científico publicado en 2003

Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression

artículo científico publicado en 2010

Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia

artículo científico publicado en 2013

Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide

artículo científico publicado en 2014

Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia

artículo científico publicado en 2009

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

artículo científico publicado en 2018

Invasive fungal infections in acute leukemia

artículo científico publicado en 2011

L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-induced Hyperbilirubinemia

artículo científico publicado en 2018

LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients

artículo científico publicado en 2011

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

artículo científico publicado en 2011

Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia

scholarly article by Candida Vitale & Alessandra Ferrajoli published January 2019 in Haematologica

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

artículo científico publicado en 2008

Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia ⬇️

artículo científico publicado el 25 de junio de 2013

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis

artículo científico publicado en 2009

Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib

artículo científico publicado en 2017

Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.

artículo científico publicado en 2016

Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

artículo científico publicado en 2016

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico publicado en 2015

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

artículo científico publicado en 2016

Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib

artículo científico publicado en 2017

Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis

artículo científico publicado en 2016

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

artículo científico publicado en 2014

Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant

artículo científico publicado en 2018

Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience

artículo científico publicado en 2004

Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab.

artículo científico publicado en 2016

Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

artículo científico publicado en 2015

Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia

artículo científico publicado en 2017

Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study

artículo científico publicado en 2018

Monoclonal antibodies in chronic lymphocytic leukemia

artículo científico publicado en 2006

Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity

artículo científico publicado en 2008

Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia

artículo científico publicado en 2011

Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia

artículo científico publicado en 2013

Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia

artículo científico publicado en 2003

Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia

artículo científico publicado en 2007

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

artículo científico publicado en 2009

Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome

artículo científico publicado en 2011

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

artículo científico publicado en 2016

Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma

artículo científico publicado en 2004

Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure

artículo científico publicado en 2015

Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma

artículo científico publicado en 2017

Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion

artículo científico publicado en 2014

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

artículo científico publicado en 2015

Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity

artículo científico publicado en 2016

Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies

artículo científico publicado en 2017

Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia

artículo científico publicado en 2009

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia ⬇️

artículo científico publicado el 5 de agosto de 2011

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

artículo científico publicado en 2012

Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia

artículo científico publicado en 2013

Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes

artículo científico publicado en 2005

Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia

artículo científico publicado en 2005

Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia

artículo científico publicado en 2008

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

artículo científico publicado en 2003

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms

artículo científico publicado en 2009

Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia

artículo científico publicado en 2003

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia

artículo científico publicado en 2012

Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia

artículo científico publicado en 2017

Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose c

Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia

artículo científico publicado en 2007

Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase

artículo científico publicado en 2011

Plasma Viral miRNAs Indicate a High Prevalence of Occult Viral Infections

artículo científico publicado en 2017

Pleural effusions in patients with acute leukemia and myelodysplastic syndrome

artículo científico publicado en 2012

Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study

artículo científico publicado en 2015

Postsplenectomy cytomegaloviral mononucleosis: marked lymphocytosis, TCRgamma gene rearrangements, and impaired IgM response

artículo científico publicado en 2005

Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2017

Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

artículo científico publicado en 2003

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

artículo científico publicado en 2007

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia

artículo científico publicado en 2013

Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia

artículo científico publicado en 2008

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens

artículo científico publicado en 2008

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

artículo científico publicado en 2010

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

artículo científico publicado en 2003

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

artículo científico publicado en 2004

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

artículo científico publicado en 2006

Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome

artículo científico publicado en 2004

Richter Syndrome in Chronic Lymphocytic Leukemia

artículo científico publicado en 2016

Role of angiogenesis in chronic lymphocytic leukemia

artículo científico publicado en 2006

Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial

artículo científico publicado en 2017

STAT-3 Activates NF-κB in Chronic Lymphocytic Leukemia Cells ⬇️

artículo científico publicado el 1 de marzo de 2011

STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells

STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells

artículo científico publicado en 2010

STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells

artículo científico publicado en 2018

STAT3-activated GM-CSFRα translocates to the nucleus and protects CLL cells from apoptosis

artículo científico publicado en 2014

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

artículo científico publicado en 2014

Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia

artículo científico publicado en 2015

Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes

artículo científico publicado en 2014

Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells

artículo científico publicado en 2013

Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans ⬇️

artículo científico publicado el 28 de junio de 2012

SnapShot: chronic lymphocytic leukemia

artículo científico publicado en 2014

Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia

scientific article published on 29 March 2017

Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal

artículo científico publicado en 2006

Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells

artículo científico publicado en 2014

Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls

artículo científico publicado en 2004

The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide

artículo científico publicado en 2017

The Role of Monoclonal Antibodies in the Management of Leukemia.

artículo científico publicado en 2010

The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab

artículo científico publicado en 2017

The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience

artículo científico publicado en 2015

The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia

artículo científico publicado en 2011

The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells

artículo científico publicado en 2010

Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside

artículo científico publicado en 2003

Treatment of chronic lymphocytic leukemia

artículo científico publicado en 2004

Treatment of younger patients with chronic lymphocytic leukemia

artículo científico publicado en 2010

Treatment with lenalidomide modulates T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia ⬇️

artículo científico publicado el 24 de febrero de 2011

Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome

artículo científico publicado en 2006

Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia

artículo científico publicado en 2014

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase

artículo científico publicado en 2013

Usage of erythropoiesis‐stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia ⬇️

artículo científico publicado el 24 de enero de 2011

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia

artículo científico publicado en 2005

Utility of quantitative flow cytometry immunophenotypic analysis of CD5 expression in small B-cell neoplasms

artículo científico publicado en 2014

WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML).

artículo científico publicado en 2005

WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells

artículo científico publicado en 2007

miRNAs involvement in the pathogenesis of Richter's syndrome

scholarly article by Katrien Van Roosbroeck et al published 8 November 2018 in Haematologica

microRNA Therapeutics in Cancer - An Emerging Concept

artículo científico publicado en 2016

β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia

artículo científico publicado en 2015

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda